Hydrogenology
Hydrogenology editorial study record

Hydrogen-rich saline attenuates cardiac and hepatic injury in a doxorubicin rat model by inhibiting inflammation and apoptosis

Gao Y et al. · Mediators Inflamm. 2016;2016:1320365.

PreclinicalOther formsPublished 2016
Study record, not medical adviceThis page reports one source and Hydrogenology’s source-text extraction. It does not establish that molecular hydrogen is effective, safe or appropriate for any person. Human, animal and laboratory evidence must not be treated as equivalent.
Source and classification

What kind of evidence is this?

Evidence stream

Preclinical

Reported design

Randomized controlled rat experiment of doxorubicin-associated cardiac and hepatic toxicity

Research topic

Cancer research

Administration classification

Other forms

Study result signal

Not reported in this record.

Outcome type

Not reported in this record.

Reported in the source

Methods at a glance

Population or model

Male Wistar rats receiving repeated doxorubicin injections

Sample

90 rats: normal saline n=30, doxorubicin n=30 and doxorubicin plus H₂ saline n=30

Duration

Daily H₂-saline treatment for 30 days

Intervention

0.55 mmol/L hydrogen-rich saline, 10 mL/kg intraperitoneally every day during the 30-day doxorubicin protocol

Hydrogen form

H₂ dissolved in saline — H₂ only, not Brown’s gas and not inhalation.

H₂ specification

Approximately 0.55 mmol/L dissolved H₂.

H₂ flow

Not applicable — intraperitoneal saline, not gas inhalation.

O₂ delivered with H₂

No O₂ was co-delivered as part of the intervention.

Comparator

Doxorubicin plus ordinary saline and a non-doxorubicin saline group

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Survival, echocardiography, histology, BNP, AST, ALT, albumin, ROS, MDA, inflammatory and apoptosis proteins

Reported result

Survival was 25/30 with H₂ saline versus 18/30 with doxorubicin alone. Cardiac function, tissue injury and several oxidative, inflammatory and apoptosis measures also favored H₂ saline; serum albumin did not significantly improve versus doxorubicin.

Results-extraction completeness

Dose, allocation, full methods, positive and null results checked in the open-access full text.

A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.

Interpretation limits

Cautions and applicability

Design and reporting cautions

Rat toxicity model, not a cancer-treatment trial and not evidence that H₂ changes tumor control. A published corrigendum should be consulted with the original article.

Applies directly to

Doxorubicin-associated cardiac and hepatic toxicity in rats, not patients receiving chemotherapy.

Preliminary appraisal framework

Not reported in this record.

Preliminary risk-of-bias status

Not reported in this record.

Appraisal rationale

Not reported in this record.

No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.

Provenance

Sources and record status

Identifiers

PMID: 28104928 · DOI: 10.1155/2016/1320365

Publisher access

Open-access full text is available through PMC.

Extraction basis

Open-access PMC full text and PubMed record.

Record revision

2026-08-10